Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 390
- Registration Number
- NCT00699972
- Locations
- πΊπΈ
Neurology/Johns Hopkins Hospital, Baltimore, Maryland, United States
πΊπΈThe Ohio State University Medical Center, Columbus, Ohio, United States
πΊπΈUniversity Neurology, Inc., Cincinnati, Ohio, United States
To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 389
- Registration Number
- NCT00699582
- Locations
- πΊπΈ
North Alabama Neuroscience Research Associates, Huntsville, Alabama, United States
πΊπΈUniversity of Arizona, Tucson, Arizona, United States
πΊπΈNeurosearch II, Inc., Ventura, California, United States
Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 712
- Registration Number
- NCT00700310
- Locations
- π¦πΊ
The Queen Elizabeth Hospital, Woodville, South Australia, Australia
π·πΊMoscow State University of Medicine and Dentistry, Moscow, Russian Federation
ππ°Queen Mary Hospital, Hong Kong, Hong Kong
Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00688376
- Locations
- πΊπΈ
Road Runner Research Ltd., San Antonio, Texas, United States
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT00675025
- Locations
- πΊπΈ
Metrohealth Medical Center, Cleveland, Ohio, United States
πΊπΈPhoenix Children's Hospital, Miami, Florida, United States
πΊπΈUCSD Pediatric Pharmacology Research Unit, San Diego, California, United States
ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00659958
- Locations
- πͺπΈ
Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain
πͺπΈComplejo Hospitalario Universitario 'Juan Canalejo', Coruna, Galicia, Spain
πͺπΈCentro Sanitario Complexo Hospitalario "XERAL-CALDE", Lugo, Galicia, Spain
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1061
- Registration Number
- NCT00658528
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1397
- Registration Number
- NCT00658632
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1069
- Registration Number
- NCT00658775
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
- Conditions
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00625443
- Locations
- πΊπΈ
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
πΊπΈDavis, Posteraro and Wasser, MDs, LLP, Manchester, Connecticut, United States
πΊπΈComprehensive Blood and Cancer Center, Bakersfield, California, United States